Literature DB >> 31303436

Long-term outcomes in Juvenile Myositis patients.

Vladislav Tsaltskan1, Annette Aldous2, Sam Serafi1, Anna Yakovleva2, Heidi Sami1, Gulnara Mamyrova1, Ira N Targoff3, Adam Schiffenbauer4, Frederick W Miller4, Samuel J Simmens2, Rodolfo Curiel1, Olcay Y Jones5, Lisa G Rider6.   

Abstract

OBJECTIVE: Juvenile idiopathic inflammatory myopathies (JIIM) are rare, chronic autoimmune muscle diseases of childhood, with the potential for significant morbidity. Data on long-term outcomes is limited. In this study we investigate correlations between clinical and demographic features with long-term outcomes in a referral population of adult patients with JIIM.
METHODS: Forty-nine adults with JIIM were assessed at two referral centers between 1994 and 2016. Features of active disease and damage at a cross-sectional assessment were obtained. Regression modeling was used to examine factors associated with long-term outcomes, defined by the presence of calcinosis or a higher adjusted Myositis Damage Index (MDI) score. A multivariable model of MDI was constructed using factors that were statistically significant in bivariate models.
RESULTS: At a median of 11.5 [IQR 4.5-18.9] years following diagnosis, median American College of Rheumatology (ACR) functional class was 2 [1.5-3.0], Health Assessment Questionnaire (HAQ) score was 0.4 out of 3.0 [0.0-1.0], and manual muscle testing (MMT) score was 229 out of 260 [212.6-256.8]. Median MDI score was 6.0 [3.5-8.9], with the most commonly damaged organ systems being cutaneous and musculoskeletal. Factors associated with an elevated MDI score were the presence of erythroderma and other cutaneous manifestations, disease duration, and ACR functional class. Calcinosis was present in 55% of patients. The strongest predictors of calcinosis were disease duration, periungual capillary changes, and younger age at diagnosis.
CONCLUSION: In a tertiary referral population, long-term functional outcomes of JIIM are generally favorable, with HAQ scores indicative of mild disability. Although most patients had mild disease activity and virtually all had significant disease damage, severe or systemic damage was rare. Certain clinical features are associated with long-term damage and calcinosis. Published by Elsevier Inc.

Entities:  

Keywords:  Calcinosis; Damage; Juvenile dermatomyositis; Outcome; Treatment

Year:  2019        PMID: 31303436      PMCID: PMC6934928          DOI: 10.1016/j.semarthrit.2019.06.014

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  29 in total

Review 1.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 2.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

3.  Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study.

Authors:  P Mathiesen; H Hegaard; T Herlin; M Zak; F K Pedersen; S Nielsen
Journal:  Scand J Rheumatol       Date:  2011-11-01       Impact factor: 3.641

4.  Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.

Authors:  Kathryn Phillippi; Mark Hoeltzel; Angela Byun Robinson; Susan Kim
Journal:  J Pediatr       Date:  2017-03-03       Impact factor: 4.406

5.  A novel autoantibody to a 155-kd protein is associated with dermatomyositis.

Authors:  Ira N Targoff; Gulnara Mamyrova; Edward P Trieu; Osvaldo Perurena; Bhanu Koneru; Terrance P O'Hanlon; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2006-11

6.  Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis.

Authors:  H Gunawardena; L R Wedderburn; J North; Z Betteridge; J Dunphy; H Chinoy; J E Davidson; R G Cooper; N J McHugh
Journal:  Rheumatology (Oxford)       Date:  2008-01-30       Impact factor: 7.580

7.  Medications received by patients with juvenile dermatomyositis.

Authors:  Takayuki Kishi; Nastaran Bayat; Michael M Ward; Adam M Huber; Lan Wu; Gulnara Mamyrova; Ira N Targoff; William J Warren-Hicks; Frederick W Miller; Lisa G Rider
Journal:  Semin Arthritis Rheum       Date:  2018-03-28       Impact factor: 5.532

8.  Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features.

Authors:  Elizabeth Stringer; Davinder Singh-Grewal; Brian M Feldman
Journal:  Arthritis Rheum       Date:  2008-11

9.  Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.

Authors:  Sarah L Tansley; Zoe E Betteridge; Gavin Shaddick; Harsha Gunawardena; Katie Arnold; Lucy R Wedderburn; Neil J McHugh
Journal:  Rheumatology (Oxford)       Date:  2014-07-01       Impact factor: 7.580

10.  Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.

Authors:  Claire T Deakin; Shireena A Yasin; Stefania Simou; Katie A Arnold; Sarah L Tansley; Zoe E Betteridge; Neil J McHugh; Hemlata Varsani; Janice L Holton; Thomas S Jacques; Clarissa A Pilkington; Kiran Nistala; Lucy R Wedderburn
Journal:  Arthritis Rheumatol       Date:  2016-10-09       Impact factor: 10.995

View more
  5 in total

Review 1.  Advances Toward Precision Medicine in Juvenile Dermatomyositis.

Authors:  Jessica Neely; Susan Kim
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

2.  Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry.

Authors:  Jessica Neely; Kaveh Ardalan; Adam Huber; Susan Kim
Journal:  Pediatr Rheumatol Online J       Date:  2022-07-19       Impact factor: 3.413

Review 3.  Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.

Authors:  Melody P Chung; Carrie Richardson; David Kirakossian; Amir B Orandi; Lesley A Saketkoo; Lisa G Rider; Adam Schiffenbauer; Carlos A von Mühlen; Lorinda Chung
Journal:  Autoimmun Rev       Date:  2020-03-28       Impact factor: 9.754

4.  Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study.

Authors:  Henriette Schermacher Marstein; Kristin Godang; Berit Flatø; Ivar Sjaastad; Jens Bollerslev; Helga Sanner
Journal:  Pediatr Rheumatol Online J       Date:  2021-04-26       Impact factor: 3.054

5.  Comparison of Patient-Reported Outcomes Measurement Information System Computerized Adaptive Testing Versus Fixed Short Forms in Juvenile Myositis.

Authors:  Ruchi N Patel; Valeria G Esparza; Jin-Shei Lai; Elizabeth L Gray; Bryce B Reeve; Rowland W Chang; David Cella; Kaveh Ardalan
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-07-30       Impact factor: 5.178

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.